Accepted for Publication: May 8, 2015.
Published Online: July 13, 2015. doi:10.1001/jamaneurol.2015.1276.
Study concept and design: S.-H. Kim, H. J. Kim.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: S.-H. Kim, H. J. Kim.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: S.-H. Kim, Yun, Joo, H. J. Kim.
Obtained funding: S.-H. Kim, Joo.
Administrative, technical, or material support: Hwang.
Study supervision: H. J. Kim.
Conflict of Interest Disclosures: Dr H. J. Kim has given talks, consulted with, and received honoraria from Bayer Schering Pharma, Biogen Idec, Genzyme Corp, Merck Serono, Novartis, Teva-Handok, and UCB; and received research grants from Genzyme, Kael-GemVax, and Merck Serono. He serves on a steering committee for MedImmune and as an editorial board member for Multiple Sclerosis Journal–Experimental, Translational and Clinical. No other disclosures were reported.
Funding/Support: The polymorphisms and statistical analyses in this study were supported by grant 2013R1A1A2058612 from the National Research Foundation of Korea and research grant 1410920-2 from the National Cancer Center, Republic of Korea.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.